Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

Ying Yu, Yuting Yan, Jun Wang, Wenjie Xiong, Yao Yao, Yanshan Huang, Rui Lyu, Tingyu Wang, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Zhijian Xiao, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 6089.

https://doi.org/10.1182/blood-2023-188786

Published: 2023

Journal Articles

The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma

Wenqiang Yan, Chen Qiu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Dehui Zou, Weiping Yuan, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 879.

https://doi.org/10.1182/blood-2023-180351

Published: 2023

Journal Articles

Static and Dynamic Assessment to Identify Ultra-High Risk Multiple Myeloma：Analysis for Patients with Overall Survival No More Than Three Years

Yan Xu, Gang An, Shuhui Deng, Weiwei Sui, Wei Liu, Wenyang Huang, Tingyu Wang, Shuhua Yi, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6701.

https://doi.org/10.1182/blood-2023-189353

Published: 2023

Journal Articles

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Wei Liu, Yi Wang, Yan Xu, Chenxing Du, Qi Wang, Tingyu Wang, Wenyang Huang, Shuaishuai Zhang, Shuhua Yi, Yuting Yan, Tengteng Yu, Weiwei Sui, Gang An, Rui Lyu, Huimin Liu, Wenjie Xiong, Mingwei Fu, Dehui Zou, Lugui Qiu

Blood (2023) 142 (Supplement 1): 6232.

https://doi.org/10.1182/blood-2023-185669

Published: 2023

Journal Articles

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Yanshan Huang, Yuting Yan, Ying Yu, Li Yuxi, Rui Lv, Tingyu Wang, Wenjie Xiong, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2023-188881

Published: 2023

Journal Articles

Development and Validation of an Individualized and Weighted Prognostic Model in Patients with Newly Diagnosed Multiple Myeloma

Wenqiang Yan, Xuehan Mao, David E. Mery, Yan Xu, Weiwei Sui, Shuhui Deng, Dehui Zou, John D Shaughnessy, Jr, Kenneth C. Anderson, Fenghuang Zhan, Lugui Qiu, Gang An

Blood (2023) 142 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2023-182598

Published: 2023

Journal Articles

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Li Yuxi, Ying Yu, Yanshan Huang, Rui Cui, Jingwen Sun, Rui Lyu, Tingyu Wang, Wenjie Xiong, Yuting Yan, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2023-186068

Published: 2023

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood (2023) 142 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2023-184868

Published: 2023

Journal Articles

R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma

Shuhua Yi, Yi Wang, Yuting Yan, Jiawen Chen, Wei Liu, Tingyu Wang, Gang An, Weiwei Sui, Wenyang Huang, Xiong Wenjie, Huimin Liu, Qi Sun, Huijun Wang, Zhijian Xiao, Jianxiang Wang, Dehui Zou, Lugui Qiu

Blood (2022) 140 (Supplement 1): 6512–6513.

https://doi.org/10.1182/blood-2022-165237

Published: 2022

Journal Articles

The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma

Huishou Fan, Wenqiang Yan, Jingyu Xu, Chenxing Du, Weiwei Sui, Shuhui Deng, Dehui Zou, Lugui Qiu, Gang An

Blood (2022) 140 (Supplement 1): 4371–4373.

https://doi.org/10.1182/blood-2022-157223

Published: 2022

Journal Articles

Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study

Ying Yu, ShuHua Yi, Xiong Wenjie, Tingyu Wang, Yuting Yan, Wei Liu, Weiwei Sui, Gang An, Yan Xu, Huimin Liu, Wenyang Huang, Dehui Zou, Lugui Qiu

Blood (2022) 140 (Supplement 1): 3587–3588.

https://doi.org/10.1182/blood-2022-162338

Published: 2022

Journal Articles

Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Jingyu Xu, Lingna Li, Wenqiang Yan, Huishou Fan, Jiahui Liu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu, Gang An

Blood (2022) 140 (Supplement 1): 10011–10012.

https://doi.org/10.1182/blood-2022-165889

Published: 2022

Journal Articles

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

Wei Liu, Hesong Zou, Yan Xu, Huimin Liu, Chenxing Du, Rui Lv, Wenyang Huang, Weiwei Sui, Shuhua Yi, Lulu Lv, Lugui Qiu, Jianxiang Wang, Dehui Zou

Blood (2022) 140 (Supplement 1): 7472–7473.

https://doi.org/10.1182/blood-2022-166451

Published: 2022

Journal Articles

Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?

Wenqiang Yan, Lingna Li, Huishou Fan, Jingyu Xu, Shuhui Deng, Weiwei Sui, Yan Xu, Dehui Zou, Lugui Qiu, Gang An

Blood (2022) 140 (Supplement 1): 7255–7256.

https://doi.org/10.1182/blood-2022-158751

Published: 2022

Journal Articles

Multiple Myeloma-Derived Mir-27b-3p Facilitates Tumor Progression Via Promoting Tumor Cell Proliferation and Immunosuppressive Microenvironment

Xiaojing Wei, Zhen Yu, Hao Sun, Lixin Gong, Lanting Liu, Teng Fang, Yi He, Tingyu Wang, Weiwei Sui, Yan Xu, Gang An, Xiaoke Ma, Lugui Qiu, Mu Hao

Blood (2022) 140 (Supplement 1): 7106–7107.

https://doi.org/10.1182/blood-2022-156759

Published: 2022

Journal Articles

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma

Huimin Liu, Hesong Zou, Wei Liu, Wenyang Huang, Shuhui Deng, Rui Lv, Weiwei Sui, Yan Xu, Shuhua Yi, Tingyu Wang, Mingwei Fu, Gang An, Yaozhong Zhao, Lugui Qiu, Dehui Zou

Blood (2022) 140 (Supplement 1): 10585–10586.

https://doi.org/10.1182/blood-2022-163258

Published: 2022

Journal Articles

Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 1830.

https://doi.org/10.1182/blood-2021-150037

Published: 2021

Journal Articles

Purine Nucleoside Analogs Plus Rituximab Is an Effective Treatment Choice for Hairy Cell Leukemia-Variant: Results from a Single Center in China

Tingyu Wang, Yi Wang, Ru Li, Ying Yu, Jiawen Chen, Rui Lyu, Wenjie Xiong, Qi Wang, Wei Liu, Wenyang Huang, Weiwei Sui, Gang An, Yan Xu, Dehui Zou, Jianxiang Wang, Lugui Qiu, Shuhua Yi

Blood (2021) 138 (Supplement 1): 3547.

https://doi.org/10.1182/blood-2021-150141

Published: 2021

Journal Articles

Rituximab Maintenance Benefits Less for Follicular Lymphoma Patients with Low Risk of the Follicular Lymphoma International Index

Tingyu Wang, Ru Li, Rui Lv, Ying Yu, Jiawen Chen, Wenjie Xiong, Qi Wang, Wei Liu, Wenyang Huang, Weiwei Sui, Gang An, Yan Xu, Dehui Zou, Jianxiang Wang, Lugui Qiu, Shuhua Yi, Yi Wang

Blood (2021) 138 (Supplement 1): 3544.

https://doi.org/10.1182/blood-2021-147114

Published: 2021

Journal Articles

Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)

Wenqiang Yan, Huishou Fan, Jingyu Xu, Jiahui Liu, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu, Gang An

Blood (2021) 138 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2021-149464

Published: 2021

NARROW

The Incidence, Clinical Application and Prognostic Significance of MYD88 and CXCR4 Mutation in Chinese Patients with Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia

The Specific Transcriptional Signature and Clonal Selection of MGUS-like Profile Predict an Exceptionally Favorable Prognosis in Patients with Newly-Diagnosed Multiple Myeloma

Static and Dynamic Assessment to Identify Ultra-High Risk Multiple Myeloma：Analysis for Patients with Overall Survival No More Than Three Years

Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Development and Validation of an Individualized and Weighted Prognostic Model in Patients with Newly Diagnosed Multiple Myeloma

Classification of NK-Large Granular Lymphocytic Leukemia By CD56 Expression

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma

The Impact of Dynamic Assessment of Risk Stratification at the Time of Disease Progression in Patients with Multiple Myeloma

Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study

Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

Is the Second Revision of the International Staging System (R2-ISS) for Multiple Myeloma Valid in a Real-World Population from China?

Multiple Myeloma-Derived Mir-27b-3p Facilitates Tumor Progression Via Promoting Tumor Cell Proliferation and Immunosuppressive Microenvironment

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma

Updated Phase 1 Results of C-CAR088, an Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma

Purine Nucleoside Analogs Plus Rituximab Is an Effective Treatment Choice for Hairy Cell Leukemia-Variant: Results from a Single Center in China

Rituximab Maintenance Benefits Less for Follicular Lymphoma Patients with Low Risk of the Follicular Lymphoma International Index

Real-World Retrospective Study of 46 Patients with Macrofocal Multiple Myeloma (MFMM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only